IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares

Stock News

Nov 07

IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1174217431"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174217431\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174217431?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174217431","market":"sh","top_or_hot":-1,"title":"IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-07 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1174217431","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174217431","pubTimestamp":1762512132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01541":"宜明昂科-B"},"translate_title":"IMMUNEONCO-B(01541)执行董事田文智增持5万股H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}